| Learn more, watch RA: a mother's story. - Video Abbott Presents Do-It-Yourself Home Makeover Tips for Arthritis Awareness Month feedproxy.google.com |
U.S. to Detail Free Health Services The Obama administration will unveil new rules specifying which preventive health services will be free to consumers under the new health law. online.wsj.com |
Teva Looks to Latin America for Growth The Burrill Report submits: By Michael FitzhughTeva (TEVA) is joining some of the pharmaceutical industry's biggest players in looking to gain ground through acquisitions and expanded promotion in the emerging generics markets of Latin America, especially Mexico and Brazil. The Israeli company is restructuring its international group, it says, combining the management of its North and South America businesses under one division led by the company's current North America CEO and president, William Marth. Complete Story » seekingalpha.com |
Regulators Sue Juice Maker POM The FTC sued POM Wonderful, maker of a popular pomegranate juice, alleging unsubstantiated health claims. online.wsj.com |
Cleveland BioLabs' Unfounded Fear of Dilution M.E. Garza submits: The last time shares of Cleveland Biolabs (CBLI) went on a run like they've seen the past few weeks, the company hit shareholders with news that it was raising money, and diluting shares. You can't blame cautious investors for over-reacting to news three days ago that the Company had filed a registration to "sell, from time to time, up to 7,808,859 shares of Common Stock on behalf of Selling Shareholders." After the news, the stock price declined 4.57%, but if the language used in these legal filings were written in plain english, investors would have realized that this filing is not indicative of future dillution. This is a smart company making sure that anyone holding a Series B Class of Warrants that were issued in a private placement back in 2007 has to pay if they want to sell them now that the stock is trading above $5.99. If the Company hadn't filed this registration, then theoretically, the shares underlying these warrants could be sold at a higher price (hint: much higher prices are expected) without direct proceeds to the Company.Complete Story » seekingalpha.com |